Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sristi Jayaswal

Is DexCom Stock Underperforming the Nasdaq?

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. Valued at a market capitalization of $28.1 billion, the company’s offerings include Dexcom G7, G7 15 Day, Dexcom G6, Dexcom ONE+, and more.

Companies with a market capitalization of $10 billion or more are typically referred to as "large-cap stocks." DXCM fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical devices industry. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.